Abstract 1067P
Background
Immune checkpoint inhibitors (ICIs) are used for the treatment of various tumours. They are amongst the best-selling cancer drugs. The introduction of several new ICIs in the past few years has not resulted in price competition. From clinical and societal perspectives, it is worthwhile to investigate whether the six available ICIs are therapeutically interchangeable. If so, this may facilitate use and stimulate price reduction by competition.
Methods
We investigated by means of a literature review, whether the ICIs for the indications with the greatest expenditure and number of patients, namely lung cancer and melanoma, are being interchangeable. Due to the lack of direct comparative studies we conducted a systematic search in PubMed, Embase en de Cochrane Library to identify all eligible (network)meta-analyses (NMA) until November 2022. Literature search terms used were “network meta-analysis” ’PD[L] 1” AND non small lung carcinoma AND melanoma. Only NMA’s including randomized clinical trials that compared the efficacy (overall survival and progression free survival) and safety (treatment related side-effects) of the PD-(L)1 inhibitors nivolumab, pembrolizumab, atezolizumab, durvalumab and/or cemiplimab with or without chemotherapy to chemotherapy were eligible.
Results
A total of 3 NMA’s involving patients with advanced NSCLC were included, and one NMA involving not-previously treated patients with advanced melanoma. Where indications do overlap - mainly monotherapy – no studies with head-to-head comparisons of ICIs have been conducted. By indirect comparison of evidence, no clinically relevant differences in effectiveness and safety are apparent. However, the validity of these indirect comparisons have strong limitations, due to the differences in inclusion criteria and patient characteristics.
Conclusions
We conclude that the determination of interchangeability of ICIs is complicated due to the limited overlap in authorized indications and lack of direct comparison between ICIs. Where indications do overlap, we expect that any differences will have limited clinical significance. We call for (publicly funded) randomized multi-cancer trials for a direct head-to-head comparison of ICIs. Such direct comparative evidence is needed to reach a competitive field.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Dutch Health Care Institute.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1079TiP - A phase I first-in-human study of PRTH-101, an IgG1 monoclonal antibody targeting DDR1, as a monotherapy and combined with pembrolizumab in patients with advanced solid malignancies
Presenter: Shiraj Sen
Session: Poster session 19
1080TiP - An investigator-initiated phase I study to assess the safety and tolerability of ex vivo next-generation neoantigen-selected tumor-infiltrating lymphocyte (TIL) therapy in advanced immune checkpoint blockade (ICB) resistant solid tumors (NEXTGENTIL-ACT)
Presenter: Vladimir Galvao
Session: Poster session 19
1325P - Sunvozertinib as first-line treatment in NSCLC patients with EGFR Exon20 insertion mutations
Presenter: James Chih-Hsin Yang
Session: Poster session 19
1326P - Osimertinib in patients with EGFR-mutated NSCLC and leptomeningeal or brain metastases: Results of the IFCT-1804 ORBITAL trial
Presenter: David Planchard
Session: Poster session 19
1327P - First-line osimertinib in patients with EGFR mutated lung cancer with uncommon mutations (OCELOT study – interim analysis)
Presenter: Daniel Breadner
Session: Poster session 19
1328P - Analysis of data from the AENEAS study assessing the third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI), aumolertinib, and virtual comparison with osimertinib
Presenter: Meredith LaRose
Session: Poster session 19
1329P - FIND: A phase II study to evaluate the efficacy of erdafitinib in FGFR-altered NSCLC
Presenter: Lucia Nogova
Session: Poster session 19
1330P - Updated results of the efficacy and safety of KN046 (a bispecific anti-PD-L1/CTLA-4) in patients with metastatic non-small cell lung cancer (NSCLC) who failed prior EGFR-TKI(s)
Presenter: Caicun Zhou
Session: Poster session 19